中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere Unveils Latest Clinical Data of Iguratimod and Abatacept at EULAR

The European Alliance of Associations for Rheumatology（EULAR）2021 Virtual Congress was held online from 2nd to 5th June (Central European Summer Time)...

2021-06-10
Simcere Published its First Environmental, Social and Governance (ESG) Report

On May 25, 2021, Simcere Pharmaceutical Group LTD. (2096.HK) released its first Environmental, Social and Governance (ESG) report. It mainly discl...

2021-05-26
Simcere Will Announce Progress of Multiple Clinical Research on Antitumor Drugs at the 2021 ASCO Annual Meeting

The 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO) - Virtual Conference will be held online from June 4th to 8th, 2021 (Easte...

2021-05-26
Simcere Enters into Partnership with Kazia Therapeutics for Paxalisib in Greater China

NANJING, China, March 29, 2021 – Simcere Pharmaceutical Group Ltd (HKSE: 2096), today announces that its affiliate entered into an exclusive license...

2021-03-30
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.